Noxafil antifungal agent for invasive Aspergillus and Candida prophylaxis gets FDA approval
PRESS RELEASE The U.S. Food and Drug Administration has approved NOXAFIL® (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Merck’s antifungal agent is also marketed More...
Swiss pharma company, Basilea, receives FDA Qualified Infectious Disease Product designation for fungal drug, isavuconazole
PRESS RELEASE Basilea Pharmaceutica Ltd. announced Thursday that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive More...
